Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types
about
Involvement of caspase 8 and c-FLIPL in the proangiogenic effects of the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)Transcription initiation sites and promoter structure of the human TRAIL-R3 geneInsulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitroImmune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data.Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosisPotential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarctionSynergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinomaCellular and molecular regulation of spiral artery remodelling: lessons from the cardiovascular fieldSoluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.TRAIL in cancer therapy: present and future challenges.Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand.Human and simian immunodeficiency virus-mediated upregulation of the apoptotic factor TRAIL occurs in antigen-presenting cells from AIDS-susceptible but not from AIDS-resistant species.Mechanisms of resistance to TRAIL-induced apoptosis in cancer.The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblastsTumor necrosis factor-related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotypeNF-kappaB activation in melanoma.TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma.The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death.Amaryllidaceae isocarbostyril alkaloids and their derivatives as promising antitumor agentsTumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells after Treatment with Xanthohumol-A Natural Compound Present in Humulus lupulus L.Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways.Trophoblast-mediated spiral artery remodelling: a role for apoptosis.TRAIL-coated leukocytes that kill cancer cells in the circulation.Resistance to TRAIL and how to surmount it.Leukocytes as carriers for targeted cancer drug delivery.Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions.Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.Specific Design of Titanium(IV) Phenolato Chelates Yields Stable and Accessible, Effective and Selective Anticancer Agents.Chloroquine enhances TRAIL-mediated apoptosis through up-regulation of DR5 by stabilization of mRNA and protein in cancer cells.Highly Stable Tetra-Phenolato Titanium(IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity.AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.Involvement of PAR-4 in cannabinoid-dependent sensitization of osteosarcoma cells to TRAIL-induced apoptosis.Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.EBV B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis.Role of the eIF4E binding protein 4E-BP1 in regulation of the sensitivity of human pancreatic cancer cells to TRAIL and celastrol-induced apoptosis.
P2860
Q24321282-6CB34148-489E-410E-99CE-AA696EF61DD1Q28213507-45A74E11-F1CD-4D1D-95AE-233BEF953A9AQ28564398-15915698-7F3E-4BFE-8CCE-CE1954BC5A51Q30985619-3CDF16D9-1D7B-4C9A-A036-E647F4B2405DQ33378957-B54EEC9D-DB8A-4145-AF9B-AFB10DB64037Q33409850-964DCA3B-E1E5-4F66-8774-08116FDB0C24Q33811260-42C3333D-018A-47E4-BC27-316F2795F965Q33901191-A8476215-002E-4DFA-BA81-EC2C495EBF19Q33910907-91842F27-758C-413A-A4B5-A3A7544C5E69Q33999606-339F71FA-A4DC-4D0A-8D45-6C0A59FF5E87Q34291312-A18945FE-24BF-4ABC-9E22-4E02F873EA45Q34313135-E9798364-63D5-4C0F-8BF4-CBCEF4A3E8F5Q34770132-AB3B95D7-5403-47AD-94BD-5D9EDC55C04DQ35914497-EEB2C105-BA36-46A1-9B4E-DD6B5D4C9CB6Q35954258-D7ED333D-D07D-4673-87C5-38C548284292Q36012574-F0CBBA30-E257-46B8-BAB5-C9E9F3FBB44DQ36058434-7142E3D8-6D43-4998-854A-88965AC91BECQ36416479-C2F8365E-1F12-482F-BE31-03B8FBBE4B0EQ36586540-BD1FAC42-51C2-42D0-A667-E535608F2D0DQ36674724-ED1D4512-7085-4D1F-A49D-4712B4D50889Q36831335-22248BE6-6591-4538-91DD-8F93BF0D4443Q37050555-E91EDD0D-BDE6-4E1E-8A7A-D549769E41CAQ37061991-D0B5D526-9292-4715-B57C-C8246ACDB610Q37392325-F9EAF68C-CAB4-4EF4-B55C-5FB448056415Q37519654-047B7A82-36CE-4ED2-8778-4CF821BBB0F8Q37992546-D5A9D706-24C5-4806-9A79-8DBD1ADFB8B9Q38255704-94602728-F89C-493B-A6D8-62D33649C8B0Q38260461-D4EC9BDE-E4F8-4EA4-B0C7-89AE04F7CBCAQ38307538-0D32FFEB-0D5A-4AAA-B6AC-D3CA76D0F662Q38446362-32FEB728-86DC-4673-B410-2EB3A0CCA507Q38557486-40ADE136-4BE8-403C-903D-620E4E4725CFQ38601593-047FB584-9A85-4E8C-A38E-B5D68023E09CQ38763409-196E06BC-E99E-4D35-B827-F4824129EE49Q38787312-A24A3F0B-143D-4392-B30A-FA76FAF00053Q38827449-DAAC6233-B4FC-473F-8718-C7EFD4EE2D81Q38960411-26462CF9-C8BD-4AF2-BB1E-AC82DC4AEEAAQ38998620-C5084C48-26EF-4B91-BBA5-A2EF5003D9F0Q39127090-BDF2E047-A052-4593-91F8-4E0B7E58D0F1Q39133257-AB76B4BE-1EE4-4134-B99F-945CA006D3F0Q39144112-F68AA200-4B5C-415D-8B46-BF2581AA9776
P2860
Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Mechanisms of resistance of no ...... y between different cell types
@ast
Mechanisms of resistance of no ...... y between different cell types
@en
Mechanisms of resistance of no ...... y between different cell types
@nl
type
label
Mechanisms of resistance of no ...... y between different cell types
@ast
Mechanisms of resistance of no ...... y between different cell types
@en
Mechanisms of resistance of no ...... y between different cell types
@nl
prefLabel
Mechanisms of resistance of no ...... y between different cell types
@ast
Mechanisms of resistance of no ...... y between different cell types
@en
Mechanisms of resistance of no ...... y between different cell types
@nl
P2093
P2860
P3181
P1433
P1476
Mechanisms of resistance of no ...... y between different cell types
@en
P2093
P2860
P304
P3181
P356
10.1016/S0014-5793(00)02042-1
P407
P577
2000-10-01T00:00:00Z